The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Rimatil     (2S)-2-[(2-methyl-2- sulfanyl...

Synonyms: Bucilamina, Tiobutarit, Thiobutarit, bucillamine, Bucillaminum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01809


High impact information on D01809

  • In the ex vivo models, bucillamine treatment significantly improved portal vein blood flow and bile production, preserved normal liver architecture, and significantly reduced liver enzyme release and indices of oxidative stress [6].
  • Initially, her arthritis had been well controlled with methotrexate and corticosteroids, but the RA activity became difficult to control in spite of addition of bucillamine to the treatment regimen and repeated arthrocentesis with infusion of corticosteroid into her swollen joints [7].
  • Of the six agents tested, only the thiol antioxidants, BUC and NAC, were effective at preventing a decrease in intracellular reduced glutathione:glutathione disulfide ratios, protecting cells from protein and lipid oxidation, and preventing heme oxygenase 1 expression [8].
  • Our data demonstrate that NAC and BUC effectively inhibited the adjuvant effects of DEP in the induction of OVA-specific IgE and IgG1 production [8].
  • Furthermore, the same concentration of bucillamine inhibited transendothelial migration of PHA-activated T cells, and reduced the expression level of CD44 on T cells [9].

Chemical compound and disease context of D01809


Biological context of D01809


Anatomical context of D01809


Associations of D01809 with other chemical compounds


Gene context of D01809


Analytical, diagnostic and therapeutic context of D01809


  1. The role of a mitochondrial pathway in the induction of apoptosis by chemicals extracted from diesel exhaust particles. Hiura, T.S., Li, N., Kaplan, R., Horwitz, M., Seagrave, J.C., Nel, A.E. J. Immunol. (2000) [Pubmed]
  2. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. Distler, J.H., Hagen, C., Hirth, A., Müller-Ladner, U., Lorenz, H.M., del Rosso, A., Michel, B.A., Gay, R.E., Nanagara, R., Nishioka, K., Matucci-Cerinic, M., Kalden, J.R., Gay, S., Distler, O. Mol. Pharmacol. (2004) [Pubmed]
  3. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Yanagi, Y., Tamaki, Y., Obata, R., Muranaka, K., Homma, N., Matsuoka, H., Mano, H. Invest. Ophthalmol. Vis. Sci. (2002) [Pubmed]
  4. Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine. Koyama, S., Takagi, H., Otani, A., Oh, H., Nishimura, K., Honda, Y. Br. J. Pharmacol. (2002) [Pubmed]
  5. A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis. Yoshida, A., Morozumi, K., Takeda, A., Koyama, K., Oikawa, T., Fujinami, T. Am. J. Kidney Dis. (1992) [Pubmed]
  6. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Amersi, F., Nelson, S.K., Shen, X.D., Kato, H., Melinek, J., Kupiec-Weglinski, J.W., Horwitz, L.D., Busuttil, R.W., Horwitz, M.A. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  7. Simultaneous, clonally identical T cell expansion in tonsil and synovium in a patient with rheumatoid arthritis and chronic tonsillitis. Kawano, M., Okada, K., Muramoto, H., Morishita, H., Omura, T., Inoue, R., Kitajima, S., Katano, K., Koni, I., Mabuchi, H., Yachie, A. Arthritis Rheum. (2003) [Pubmed]
  8. Thiol antioxidants inhibit the adjuvant effects of aerosolized diesel exhaust particles in a murine model for ovalbumin sensitization. Whitekus, M.J., Li, N., Zhang, M., Wang, M., Horwitz, M.A., Nelson, S.K., Horwitz, L.D., Brechun, N., Diaz-Sanchez, D., Nel, A.E. J. Immunol. (2002) [Pubmed]
  9. Novel in vitro effects of bucillamine: inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells. Munakata, Y., Iwata, S., Dobers, J., Ishii, T., Nori, M., Tanaka, H., Morimoto, C. Arthritis Rheum. (2000) [Pubmed]
  10. In vitro and in vivo inhibition of activation induced T cell apoptosis by bucillamine. Okazaki, H., Sato, H., Kamimura, T., Hirata, D., Iwamoto, M., Yoshio, T., Mimori, A., Masuyama, J.I., Kano, S., Minota, S. J. Rheumatol. (2000) [Pubmed]
  11. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Nagashima, M., Matsuoka, T., Saitoh, K., Koyama, T., Kikuchi, O., Yoshino, S. Clin. Exp. Rheumatol. (2006) [Pubmed]
  12. Bucillamine-induced pemphigus vulgaris in a patient with rheumatoid arthritis and polymyositis overlap syndrome. Hur, J.W., Lee, C.W., Yoo, D.H. J. Korean Med. Sci. (2006) [Pubmed]
  13. Generation of reactive oxygen species is required for bucillamine, a novel anti-rheumatic drug, to induce apoptosis in concert with copper. Sawada, T., Hashimoto, S., Furukawa, H., Tohma, S., Inoue, T., Ito, K. Immunopharmacology (1997) [Pubmed]
  14. Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases. Narazaki, R., Otagiri, M. Pharm. Res. (1997) [Pubmed]
  15. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. Hashimoto, K., Lipsky, P.E. J. Rheumatol. (1993) [Pubmed]
  16. Down-regulation by bucillamine of lamina propria leucocytes in the rat colitis model. Oshitani, N., Matsumoto, T., Nakamura, S., Arakawa, T., Kitano, A., Kuroki, T. Clin. Exp. Pharmacol. Physiol. (1999) [Pubmed]
  17. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Hirohata, S., Lipsky, P.E. Arthritis Rheum. (1994) [Pubmed]
  18. Bucillamine induces glutathione biosynthesis via activation of the transcription factor Nrf2. Wielandt, A.M., Vollrath, V., Farias, M., Chianale, J. Biochem. Pharmacol. (2006) [Pubmed]
  19. The role of thiols in liver ischemia-reperfusion injury. Glantzounis, G.K., Yang, W., Koti, R.S., Mikhailidis, D.P., Seifalian, A.M., Davidson, B.R. Curr. Pharm. Des. (2006) [Pubmed]
  20. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Nagashima, M., Yoshino, S., Aono, H., Takai, M., Sasano, M. Clin. Exp. Immunol. (1999) [Pubmed]
  21. Bucillamine inhibits T cell adhesion to human endothelial cells. Eguchi, K., Kawakami, A., Ida, H., Nakashima, M., Yamashita, I., Sakai, M., Shimada, H., Terada, K., Fukuda, T., Ishimaru, T. J. Rheumatol. (1992) [Pubmed]
  22. Inhibitory effects of bucillamine on increased blood-retinal barrier permeability in streptozotocin-induced diabetic rats. Hikichi, T., Mori, F., Nakamura, M., Shishido, N., Sasaki, M., Horikawa, Y., Yoshida, A. Curr. Eye Res. (2002) [Pubmed]
  23. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine. Girgis, L., Conaghan, P.G., Brooks, P. Current opinion in rheumatology. (1994) [Pubmed]
  24. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. Kikuchi, H., Isshi, K., Hirohata, S. Int. Immunopharmacol. (2004) [Pubmed]
  25. Modulatory effect of bucillamine (SA96) on interleukin-1-and/or -2-induced proliferation of T lymphocytes. Sasano, M., Goto, M., Nishioka, K. Agents Actions (1990) [Pubmed]
  26. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats. Hayashi, M., Matsunaga, K., Okahara, A., Mita, S. J. Rheumatol. (1991) [Pubmed]
WikiGenes - Universities